AbbVie Inc. (ABBV)
USD 173.02
(-1.35%)
USD 173.02
(-1.35%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 4.86 Billion USD | -58.91% |
| 2022 | 11.83 Billion USD | 2.55% |
| 2021 | 11.54 Billion USD | 150.04% |
| 2020 | 4.61 Billion USD | -41.44% |
| 2019 | 7.88 Billion USD | 38.6% |
| 2018 | 5.68 Billion USD | 7.12% |
| 2017 | 5.3 Billion USD | -10.82% |
| 2016 | 5.95 Billion USD | 15.73% |
| 2015 | 5.14 Billion USD | 189.97% |
| 2014 | 1.77 Billion USD | -57.03% |
| 2013 | 4.12 Billion USD | -21.74% |
| 2012 | 5.27 Billion USD | 53.65% |
| 2011 | 3.43 Billion USD | -17.83% |
| 2010 | 4.17 Billion USD | -9.89% |
| 2009 | 4.63 Billion USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.36 Billion USD | 66.55% |
| 2024 Q3 | 1.56 Billion USD | 13.94% |
| 2024 Q2 | 1.37 Billion USD | 0.07% |
| 2023 Q2 | 2.02 Billion USD | 746.86% |
| 2023 Q4 | 822 Million USD | -53.77% |
| 2023 FY | 4.86 Billion USD | -58.91% |
| 2023 Q1 | 239 Million USD | -90.34% |
| 2023 Q3 | 1.77 Billion USD | -12.15% |
| 2022 Q1 | 4.49 Billion USD | 11.03% |
| 2022 Q3 | 3.94 Billion USD | 327.38% |
| 2022 Q4 | 2.47 Billion USD | -37.38% |
| 2022 FY | 11.83 Billion USD | 2.55% |
| 2022 Q2 | 924 Million USD | -79.42% |
| 2021 Q2 | 766 Million USD | -78.45% |
| 2021 Q3 | 3.17 Billion USD | 315.01% |
| 2021 Q4 | 4.04 Billion USD | 27.21% |
| 2021 FY | 11.54 Billion USD | 150.04% |
| 2021 Q1 | 3.55 Billion USD | 9775.0% |
| 2020 Q3 | 2.3 Billion USD | 412.74% |
| 2020 Q4 | 36 Million USD | -98.44% |
| 2020 FY | 4.61 Billion USD | -41.44% |
| 2020 Q2 | -738 Million USD | -124.52% |
| 2020 Q1 | 3.01 Billion USD | 7.46% |
| 2019 FY | 7.88 Billion USD | 38.6% |
| 2019 Q1 | 2.45 Billion USD | 234.5% |
| 2019 Q2 | 741 Million USD | -69.83% |
| 2019 Q3 | 1.88 Billion USD | 154.25% |
| 2019 Q4 | 2.8 Billion USD | 48.67% |
| 2018 Q1 | 2.78 Billion USD | 5251.92% |
| 2018 FY | 5.68 Billion USD | 7.12% |
| 2018 Q4 | -1.82 Billion USD | -166.47% |
| 2018 Q3 | 2.74 Billion USD | 38.53% |
| 2018 Q2 | 1.98 Billion USD | -28.75% |
| 2017 Q1 | 1.71 Billion USD | 23.01% |
| 2017 FY | 5.3 Billion USD | -10.82% |
| 2017 Q4 | 52 Million USD | -96.81% |
| 2017 Q2 | 1.91 Billion USD | 11.92% |
| 2017 Q3 | 1.63 Billion USD | -14.83% |
| 2016 Q3 | 1.59 Billion USD | -0.75% |
| 2016 Q4 | 1.39 Billion USD | -12.95% |
| 2016 FY | 5.95 Billion USD | 15.73% |
| 2016 Q1 | 1.35 Billion USD | -10.74% |
| 2016 Q2 | 1.61 Billion USD | 18.91% |
| 2015 Q3 | 1.23 Billion USD | -9.3% |
| 2015 FY | 5.14 Billion USD | 189.97% |
| 2015 Q4 | 1.51 Billion USD | 22.44% |
| 2015 Q2 | 1.36 Billion USD | 33.66% |
| 2015 Q1 | 1.02 Billion USD | 226.17% |
| 2014 Q2 | 1.09 Billion USD | 12.04% |
| 2014 Q1 | 980 Million USD | -13.12% |
| 2014 FY | 1.77 Billion USD | -57.03% |
| 2014 Q4 | -810 Million USD | -260.08% |
| 2014 Q3 | 506 Million USD | -53.92% |
| 2013 Q4 | 1.12 Billion USD | 17.01% |
| 2013 Q3 | 964 Million USD | -9.74% |
| 2013 Q2 | 1.06 Billion USD | 10.33% |
| 2013 Q1 | 968 Million USD | -37.13% |
| 2013 FY | 4.12 Billion USD | -21.74% |
| 2012 Q1 | 883.27 Million USD | -23.7% |
| 2012 FY | 5.27 Billion USD | 53.65% |
| 2012 Q2 | 1.26 Billion USD | 43.44% |
| 2012 Q3 | 1.58 Billion USD | 25.1% |
| 2012 Q4 | 1.53 Billion USD | -2.86% |
| 2011 Q1 | 723.19 Million USD | 0.0% |
| 2011 Q3 | 12.33 Million USD | -99.2% |
| 2011 Q4 | 1.15 Billion USD | 9284.38% |
| 2011 Q2 | 1.54 Billion USD | 112.95% |
| 2011 FY | 3.43 Billion USD | -17.83% |
| 2010 FY | 4.17 Billion USD | -9.89% |
| 2009 FY | 4.63 Billion USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bristol-Myers Squibb Company | 8.02 Billion USD | 39.402% |
| Bristol-Myers Squibb Company Ce | 8.02 Billion USD | 39.402% |
| Johnson & Johnson | 35.15 Billion USD | 86.166% |
| Eli Lilly and Company | 5.24 Billion USD | 7.202% |
| Merck & Co., Inc. | 365 Million USD | -1232.329% |
| Novartis AG | 14.85 Billion USD | 67.253% |
| Organon & Co. | 1.02 Billion USD | -375.367% |
| Pfizer Inc. | 2.11 Billion USD | -129.495% |